A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Trial Profile

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2018

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 18 Jan 2018 Planned number of patients changed from 225 to 360, according to an SymBio Pharmaceuticals media release.
    • 18 Jan 2018 According to an SymBio Pharmaceuticals media release, based on an interim analysis, the independent Data Monitoring Committee (DMC) has recommended to increase the trial enrollment plan form current 225 patients to total of 360 patients.
    • 06 Dec 2017 Planned End Date changed from 1 Sep 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top